Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer Vaccine
Human papillomavirus-16 vaccine prevents cervical intraepithelial neoplasia
March 23rd, 2006
Results of a randomized controlled trial indicated that a human papillomavirus-16 vaccine prevents cervical intraepithelial neoplasia. According to a study from the United States, "Human papillomavirus (HPV) virus-like particle (VLP) vaccines have demonstrated effectiveness in preventing persistent HPV infections. Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2-3 has not yet been established. We present results from an HPV-16 L1 VLP vaccine trial through 48 months." "A total of 2,391 women, aged 16-23 years, participated in a randomized, double-blind, placebo-controlled trial,"...
Source: Women's Health Weekly (2006-03-23)
|
